Published in N Engl J Med on January 30, 2015
Using Fitbit to Monitor Ambulation in Patients After Surgery. | NCT02741895
Incontinence and Quality of Life in Children With Spina Bifida | NCT03410667
The Genomic Ascertainment Cohort | NCT03632239
Genetic Predisposition to Food Cue Reactivity in Children | NCT03766191
Personalizing Self-management in Diabetes - Pilot Study | NCT04757233
The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities. Am J Hum Genet (2015) 2.22
The FDA and genomic tests--getting regulation right. N Engl J Med (2015) 2.09
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA (2015) 2.02
The Ensembl Variant Effect Predictor. Genome Biol (2016) 1.80
Racial/ethnic standards for fetal growth: the NICHD Fetal Growth Studies. Am J Obstet Gynecol (2015) 1.79
Radiomics: Images Are More than Pictures, They Are Data. Radiology (2015) 1.68
Precision Public Health for the Era of Precision Medicine. Am J Prev Med (2015) 1.64
North Carolina Macular Dystrophy Is Caused by Dysregulation of the Retinal Transcription Factor PRDM13. Ophthalmology (2015) 1.55
Driving Innovation in Health Systems through an Apps-Based Information Economy. Cell Syst (2015) 1.51
Annual Research Review: Building a science of personalized intervention for youth mental health. J Child Psychol Psychiatry (2015) 1.43
Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses. BMJ (2016) 1.41
Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget (2016) 1.41
DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res (2015) 1.41
Overview of the BioBank Japan Project: Study design and profile. J Epidemiol (2017) 1.32
The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ (2016) 1.28
Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol (2015) 1.25
Diversity in Clinical and Biomedical Research: A Promise Yet to Be Fulfilled. PLoS Med (2015) 1.23
Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer (2016) 1.22
PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol (2015) 1.16
Molecular pathological epidemiology gives clues to paradoxical findings. Eur J Epidemiol (2015) 1.16
Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies. Nat Med (2015) 1.15
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine. Nat Rev Cardiol (2016) 1.13
Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med (2016) 1.13
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review. Circulation (2016) 1.13
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discov Today (2015) 1.12
Genetics of Inflammatory Bowel Diseases. Gastroenterology (2015) 1.11
Report of the AMIA EHR-2020 Task Force on the status and future direction of EHRs. J Am Med Inform Assoc (2015) 1.11
A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients. J Am Med Inform Assoc (2016) 1.11
Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet (2015) 1.11
The Tohoku Medical Megabank Project: Design and Mission. J Epidemiol (2016) 1.08
The future of murine sepsis and trauma research models. J Leukoc Biol (2015) 1.04
Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. Circ Res (2015) 1.02
Statistical methods for studying disease subtype heterogeneity. Stat Med (2015) 1.01
Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J (2016) 1.01
Protecting genomic data analytics in the cloud: state of the art and opportunities. BMC Med Genomics (2016) 1.00
A Federated Network for Translational Cancer Research Using Clinical Data and Biospecimens. Cancer Res (2015) 1.00
Modeling psychiatric disorders for developing effective treatments. Nat Med (2015) 0.98
The VA Point-of-Care Precision Oncology Program: Balancing Access with Rapid Learning in Molecular Cancer Medicine. Biomark Cancer (2016) 0.98
Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial). Circulation (2016) 0.97
Charting a future for epidemiologic training. Ann Epidemiol (2015) 0.97
The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica (2016) 0.97
Cancer biomarker discovery and validation. Transl Cancer Res (2015) 0.96
Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn (2015) 0.94
News from the NIH: potential contributions of the behavioral and social sciences to the precision medicine initiative. Transl Behav Med (2015) 0.94
A Survey of U.S Adults' Opinions about Conduct of a Nationwide Precision Medicine Initiative® Cohort Study of Genes and Environment. PLoS One (2016) 0.93
Metabolomics enables precision medicine: "A White Paper, Community Perspective". Metabolomics (2016) 0.93
When do confounding by indication and inadequate risk adjustment bias critical care studies? A simulation study. Crit Care (2015) 0.93
Unravelling the human genome-phenome relationship using phenome-wide association studies. Nat Rev Genet (2016) 0.92
Precision medicine: from pharmacogenomics to pharmacoproteomics. Clin Proteomics (2016) 0.92
Using e-technologies in clinical trials. Contemp Clin Trials (2015) 0.92
A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat Med (2016) 0.91
Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes. Brief Bioinform (2015) 0.91
Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations. J Physiol (2016) 0.90
Control of Body Weight by Eating Behavior in Children. Front Pediatr (2015) 0.90
Bioinformatics Workflow for Clinical Whole Genome Sequencing at Partners HealthCare Personalized Medicine. J Pers Med (2016) 0.90
New paradigms in sepsis: from prevention to protection of failing microcirculation. J Thromb Haemost (2015) 0.89
NIH Precision Medicine Initiative: Implications for Diabetes Research. Diabetes Care (2016) 0.89
Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer (2016) 0.89
Between Openness and Privacy in Genomics. PLoS Med (2016) 0.89
Genome-wide association studies of late-onset cardiovascular disease. J Mol Cell Cardiol (2015) 0.89
Citizen science or scientific citizenship? Disentangling the uses of public engagement rhetoric in national research initiatives. BMC Med Ethics (2016) 0.89
Molecular Medicine of Pulmonary Arterial Hypertension: From Population Genetics to Precision Medicine and Gene Editing. Am J Respir Crit Care Med (2016) 0.89
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun (2016) 0.89
The Geisinger MyCode community health initiative: an electronic health record-linked biobank for precision medicine research. Genet Med (2016) 0.89
Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Rev Mol Diagn (2016) 0.89
Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. Nat Rev Cancer (2015) 0.89
Developing therapeutic 'arrows' with the precision of William Tell: the time has come for targeted therapies in kidney disease. Curr Opin Nephrol Hypertens (2015) 0.88
Utilizing population variation, vaccination, and systems biology to study human immunology. Trends Immunol (2015) 0.88
Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis. Eur Child Adolesc Psychiatry (2016) 0.88
Red Blood Cell Transfusion: Precision vs Imprecision Medicine. JAMA (2015) 0.87
Candidate genetic modifiers of retinitis pigmentosa identified by exploiting natural variation in Drosophila. Hum Mol Genet (2015) 0.87
Time for Integrating Clinical, Lifestyle and Molecular Data to Predict Drug Responses. EBioMedicine (2016) 0.87
NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings. Nucleic Acids Res (2015) 0.86
Primary care providers' experiences with and perceptions of personalized genomic medicine. Can Fam Physician (2016) 0.86
From genomic medicine to precision medicine: highlights of 2015. Genome Med (2016) 0.86
Cancer prevention as part of precision medicine: 'plenty to be done'. Carcinogenesis (2015) 0.86
Signaling in Host-Associated Microbial Communities. Cell (2016) 0.86
Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol (2016) 0.86
Omics Profiling in Precision Oncology. Mol Cell Proteomics (2016) 0.85
Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nat Rev Clin Oncol (2015) 0.85
Prenatal Programming and Toxicity (PPTOX) Introduction. Endocrinology (2015) 0.85
Exploiting microRNA Specificity and Selectivity: Paving a Sustainable Path Towards Precision Medicine. Adv Exp Med Biol (2015) 0.85
Targeting Breast Cancer Metastasis. Breast Cancer (Auckl) (2015) 0.85
A method to decipher pleiotropy by detecting underlying heterogeneity driven by hidden subgroups applied to autoimmune and neuropsychiatric diseases. Nat Genet (2016) 0.85
DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients. Medicine (Baltimore) (2016) 0.85
GSA: Genome Sequence Archive(). Genomics Proteomics Bioinformatics (2017) 0.85
Personalized Proteomics: The Future of Precision Medicine. Proteomes (2016) 0.85
Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol (2016) 0.85
The CKD Classification System in the Precision Medicine Era. Clin J Am Soc Nephrol (2016) 0.85
Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet (2017) 0.84
Imaging of cerebrovascular disorders: precision medicine and the collaterome. Ann N Y Acad Sci (2015) 0.84
Recent Advances and Emerging Applications in Text and Data Mining for Biomedical Discovery. Brief Bioinform (2015) 0.84
Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape: A Conference Report From the American Heart Association Data Summit 2015. J Am Heart Assoc (2015) 0.84
The development of precision medicine in clinical practice. Clin Transl Med (2015) 0.84
Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system. Lancet (2015) 0.84
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital. Oncologist (2016) 0.84
A Bright Future for Precision Medicine: Advances in Fluorescent Chemical Probe Design and Their Clinical Application. Cell Chem Biol (2016) 0.84
The Future of Pharmaceutical Manufacturing Sciences. J Pharm Sci (2015) 0.84
Objective assessment of dietary patterns by use of metabolic phenotyping: a randomised, controlled, crossover trial. Lancet Diabetes Endocrinol (2017) 0.84
The Qatar genome: a population-specific tool for precision medicine in the Middle East. Hum Genome Var (2016) 0.84
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book (2014) 6.22
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Rescuing US biomedical research from its systemic flaws. Proc Natl Acad Sci U S A (2014) 14.78
The knockout mouse project. Nat Genet (2004) 7.80
Seeding and propagation of untransformed mouse mammary cells in the lung. Science (2008) 5.33
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Statement on scientific publication and security. Science (2003) 3.04
Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development (2004) 2.84
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A (2012) 2.52
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One (2007) 2.25
Overview of the Alliance for Cellular Signaling. Nature (2002) 2.15
Statement on the consideration of biodefence and biosecurity. Nature (2003) 2.09
Three decades of Wnts: a personal perspective on how a scientific field developed. EMBO J (2012) 1.89
Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of beta-catenin. Proc Natl Acad Sci U S A (2004) 1.89
Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev (2009) 1.76
Uncensored exchange of scientific results. Proc Natl Acad Sci U S A (2003) 1.73
Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med (2011) 1.54
Wnt/Wingless signaling through beta-catenin requires the function of both LRP/Arrow and frizzled classes of receptors. BMC Cell Biol (2003) 1.54
Ten years on--the human genome and medicine. N Engl J Med (2010) 1.52
Casein kinase Iepsilon modulates the signaling specificities of dishevelled. Mol Cell Biol (2004) 1.41
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech (2009) 1.34
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov (2014) 1.27
A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. BMC Mol Biol (2003) 1.26
Requirement for a nuclear function of beta-catenin in Wnt signaling. Mol Cell Biol (2003) 1.14
Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion. PLoS Biol (2007) 1.13
Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10/BCLb, are regulated by Ubiquilin1. Proc Natl Acad Sci U S A (2012) 1.05
Getting ready for gene-based medicine. N Engl J Med (2002) 1.00
The enlightenment returns. Science (2009) 0.97
Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells. J Biomol Screen (2009) 0.93
Receptor for hyaluronan-mediated motility isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis and a tail vein assay for metastasis. Proc Natl Acad Sci U S A (2011) 0.88
Activation of PyMT in beta cells induces irreversible hyperplasia, but oncogene-dependent acinar cell carcinomas when activated in pancreatic progenitors. PLoS One (2009) 0.87
Support for the Human Cancer Genome Project. Science (2005) 0.86
Newsmaker interview: Harold Varmus. Piloting cancer research with a shrinking budget. Interview by Jocelyn Kaiser. Science (2011) 0.78
NIH funds support more than a researcher's own lab. Nature (2008) 0.75
Progress toward public access to science. PLoS Biol (2008) 0.75
A conversation with Harold Varmus. Interview by Ushma S. Neill. J Clin Invest (2012) 0.75
Re-aim blame for NIH's hard times. Science (2006) 0.75
The weaknesses of science for profit. Oncologist (2002) 0.75
NIH cancer chief wants more with less: by Meredith Wadman. Nature (2011) 0.75
Varmus Returns to His Roots in Cancer Genetics. JAMA (2015) 0.75
A Prize for Cancer Prevention. Cell (2017) 0.75
Harold Varmus. Interview by Errol C. Friedberg. Nat Rev Mol Cell Biol (2008) 0.75